Tag: Syngene
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services
Syngene acquires its first manufacturing facility in the US
Biologics drug substance facility in Baltimore expected to enhance global innovator flexibility
Syngene earns silver rating in EcoVadis sustainability index
Achievements include 82% renewable energy use, 96% waste recycling, and strong commitment to ESG practices, ranking it among top 15% globally
Biocon reports 30% revenue increase and ₹660 crore net profit in...
Biocon's Q1FY25 performance sees 117% EBITDA growth and ₹660 crore net profit, powered by strategic partnerships and biosimilar success
Biocon’s biosimilars revenue crosses milestone of US $1 Billion in FY...
The company garnered an overall revenue of Rs 15,621 Crore in FY24, marking a remarkable 35% growth compared to the previous year
Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
The company has reported total income of Rs. 933 crores during the period ended March 31, 2024
Syngene biologics manufacturing facility to be soon operational for US &...
New facility to be operational in second half of 2024 includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Veeda Clinical Research appoints Dr Mahesh Bhalgat as Group CEO
Prior to joining Veeda, Mahesh was the COO for Syngene International (Biocon Group Company), India’s largest CRO & CDMO company
Biocon clocks Rs 4,519 crore revenue in Q3 of FY24, earns...
The company revenue in biosimilars went up by 65%; research services up by 9%; EBITDA stood at Rs 1,492 Crore, up 106%; Net Profit at Rs 660 Crore
Syngene records Rs 3,193 Crore revenue in FY23, up by 23%
Fourth quarter revenue from operations up 31% to Rs. 994 Crore and PAT up 21% to Rs. 179 Crore